Calreticulin—From the Endoplasmic Reticulum to the Plasma Membrane—Adventures of a Wandering Protein
Cancers · 17.01.2025 · 17 (2) · 288
DOI: 10.3390/cancers17020288 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.01.2025. Verfasst von Gillian C Okura und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Dalhousie University, Halifax, NS B3H 1X5, Canada. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 250 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Cancer Society and the J.D. Irving, Limited, Excellence in Cancer Research Fund, Canadian Cancer Society and the J.D. Irving, Ltd., Excellence in Cancer Research Fund.
Abstract (Originalsprache)
Calreticulin (CRT) is a 46 kDa highly conserved protein initially identified as calregulin, a prominent Ca2+-binding protein of the endoplasmic reticulum (ER). Subsequent studies have established that CRT functions in the ER’s protein folding response and Ca2+ homeostatic mechanisms. An ER retention signal on the carboxyl terminus of CRT suggested that CRT was restricted to the ER. However, the identification of CRT in the nucleus and cytosol has established that CRT is a multi-compartmental, multifunctional protein. CRT also plays an important role in cancer progression. Most recently, CRT was identified on the cell surface and shown to be a potent ‘eat-me’ signal that plays a key role in the uptake of apoptotic and viable cancer cells by phagocytes. Elevated CRT exposure on the outer leaflet of cancer cells has been linked with anticancer immunity and superior therapeutic outcomes in patients with non-small cell lung carcinoma, colorectal carcinoma, acute myeloid leukemia, ovarian cancer, and high-grade serous carcinomas. Mutations in the CRT gene have been identified in a subset of patients with myeloproliferative neoplasms. The most recent studies from our laboratory have revealed a new and significant function for extracellular CRT as a plasminogen receptor. This discovery has profound implications for our understanding of the role of CRT in myeloproliferative neoplasms, specifically, essential thrombocythemia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Dalhousie University, Halifax, NS B3H 1X5, Canada.
- Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, NS B3H 1X5, Canada.
ORCID-Profile: Gillian C Okura, David M Waisman
Förderung
- Canadian Cancer Society and the J.D. Irving, Limited, Excellence in Cancer Research Fund
- Canadian Cancer Society and the J.D. Irving, Ltd., Excellence in Cancer Research Fund
Zitieren
APA
Okura, G. C., Bharadwaj, A. G., & Waisman, D. M. (2025). Calreticulin—From the Endoplasmic Reticulum to the Plasma Membrane—Adventures of a Wandering Protein. Cancers, 17(2), 288. https://doi.org/10.3390/cancers17020288
Vancouver
Okura GC, Bharadwaj AG, Waisman DM. Calreticulin—From the Endoplasmic Reticulum to the Plasma Membrane—Adventures of a Wandering Protein. Cancers. 2025;17(2):288. doi:10.3390/cancers17020288
BibTeX
@article{Okura2025,
author = {Okura, Gillian C and Bharadwaj, Alamelu G and Waisman, David M},
title = {Calreticulin—From the Endoplasmic Reticulum to the Plasma Membrane—Adventures of a Wandering Protein},
journal = {Cancers},
year = {2025},
volume = {17},
number = {2},
pages = {288},
doi = {10.3390/cancers17020288}
}
EUVIMED